The global cancer immunotherapy market reached a value of US$ 96.6 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 167.5 Billion by 2027 exhibiting a CAGR of 9.10% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Cancer is a preventable disease starting in any organ or tissue of the body on account of the abnormal cell growth that invades adjoining parts of the body and spreads to other organs. It is one of the leading causes of death globally, which is nowadays treated using cancer immunotherapy. Cancer immunotherapy offers more advantages than conventional anti-tumor therapy that can prolong progression-free survival (PFS) and overall survival (OS). It can be combined with radiation, chemotherapy, surgery, or targeted therapies to improve their effectiveness. Apart from this, as it enables the immune system to recognize, prevent, control, and eliminate cancer, cancer immunotherapy finds extensive applications in hospitals, cancer research centers, and clinics around the world.

Cancer Immunotherapy Industry Trends and Drivers:
There is currently an increase in the number of people who have cancer across the globe. This, in confluence with the burgeoning healthcare industry, represents one of the key factors propelling the growth of the market. Moreover, there are fewer side effects associated with cancer immunotherapy. As a result, there is a significant rise in the use of monoclonal antibodies to treat different types of cancer by selectively attacking cancerous cells. This, coupled with the rising prevalence of multiple myeloma and melanoma, is catalyzing the demand for cancer immunotherapy. Besides this, leading players are sponsoring patient assistance programs (PAPs) that provide financial assistance to low-income individuals for augmenting the existing prescription drug coverage. This, in turn, is positively influencing the market. Other factors strengthening the growth of the market are technological advancements in clinical therapies, extensive research and development (R&D) activities, and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global cancer immunotherapy market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapy type, application and end user.

Breakup by Therapy Type:

Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
Others

Breakup by Application:

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Others

Breakup by End User:

Hospitals
Cancer Research Centers
Clinics
Others

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck KGAA, Novartis AG, Pfizer Inc., Sanofi, and Seagen Inc. Key Questions Answered in This Report:
How has the global cancer immunotherapy market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global cancer immunotherapy market?
What are the key regional markets?
What is the breakup of the market based on the therapy type?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global cancer immunotherapy market and who are the key players?
What is the degree of competition in the industry?